WaveMan
WaveMan · Company
ONC · Beone Medicines Ltd.
> Search tickers & screens ⌘K
LIVE
← All companies

ONC BeOne Medicines (ONC) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001651308
Quote by TradingView
Form 144 · 9
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
167
13F, latest reported quarter
Conversions, 180 days
26
Codes C/M, not in net · $66.9M priced

What the filings say about ONC

Insiders, 180 days
-$339.5M net sold
12 sellers · 16% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$139.2M
9 notices

BeOne Medicines insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, BeOne Medicines Ltd. insiders sold a net $339.5M of stock across 289 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Wang Xiaodong
Director
SELL
2026-10-15 SECtraded 2026-10-13
7,167
$2.5M
+2.3%
Context
  • 27 earlier Form 4 trades (code P or S) here by this insider (27 sales), the last on Sep 28, 2026.
  • The trade is 30.0% of the 23,860 shares held after it.
  • 1 other insider sold within 30 days.
  • 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Wang Xiaodong sold about $2.5M of ONC under a 10b5-1 plan on Oct 13, 2026; 1 other insider sold within 30 days and 167 funds added in the latest 13F quarter.
Wang Xiaodong
Director
SELL
2026-10-15 SECtraded 2026-10-13
10,361
$3.6M
+2.3%
Context
  • 27 earlier Form 4 trades (code P or S) here by this insider (27 sales), the last on Sep 28, 2026.
  • The trade is 76.8% of the 13,499 shares held after it.
  • 1 other insider sold within 30 days.
  • 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Wang Xiaodong sold about $3.6M of ONC under a 10b5-1 plan on Oct 13, 2026; 1 other insider sold within 30 days and 167 funds added in the latest 13F quarter.
Wang Xiaodong
Director
SELL
2026-10-15 SECtraded 2026-10-13
5,681
$2.0M
+2.3%
Context
  • 27 earlier Form 4 trades (code P or S) here by this insider (27 sales), the last on Sep 28, 2026.
  • The trade is 72.7% of the 7,818 shares held after it.
  • 1 other insider sold within 30 days.
  • 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Wang Xiaodong sold about $2.0M of ONC under a 10b5-1 plan on Oct 13, 2026; 1 other insider sold within 30 days and 167 funds added in the latest 13F quarter.
Wang Xiaodong
Director
SELL
2026-10-15 SECtraded 2026-10-13
6,558
$2.3M
+2.3%
Context
  • 27 earlier Form 4 trades (code P or S) here by this insider (27 sales), the last on Sep 28, 2026.
  • The trade is 520.5% of the 1,260 shares held after it.
  • 1 other insider sold within 30 days.
  • 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Wang Xiaodong sold about $2.3M of ONC under a 10b5-1 plan on Oct 13, 2026; 1 other insider sold within 30 days and 167 funds added in the latest 13F quarter.
Wang Xiaodong
Director
SELL
2026-10-15 SECtraded 2026-10-13
1,260
$445.1K
+2.3%
Context
  • 27 earlier Form 4 trades (code P or S) here by this insider (27 sales), the last on Sep 28, 2026.
  • 1 other insider sold within 30 days.
  • 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Wang Xiaodong sold about $445.1K of ONC under a 10b5-1 plan on Oct 13, 2026; 1 other insider sold within 30 days and 167 funds added in the latest 13F quarter.
289 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 284 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$339.5M over 180 days
-$124.3M over 90 days
below 99% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
167 funds bought in last quarter
more than 85% of Pharma & Biotech
Revenue
+40.2% year over year
more than 73% of Pharma & Biotech
Margin
5.4% net margin
more than 77% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
2.4% of the float short (float per yahoo 2026-10-26) · 5.0 days to cover · settled 2026-09-30
below 88% of Pharma & Biotech
The situation: each line is one rule over one dataset
5 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Oct 15Director Wang Xiaodong sold $22.2M under a 10b5-1 plan (15 trades, Sep 28 to Oct 13)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 2SVP, General Counsel Lee Chan Henry sold $418.1K under a 10b5-1 plan (Sep 30)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Sep 30Officer CHAN LEE filed to sell $407.3K by Sep 30 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch ONC

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+20.4%12M
-17%-4%+10%+23%2025-102025-122026-022026-042026-062026-082026-10 2026-08-10 · OYLER JOHN sold $16.2M2026-07-15 · OYLER JOHN sold $15.2M2026-07-14 · OYLER JOHN sold $14.1M2026-07-16 · OYLER JOHN sold $13.6M2026-07-15 · OYLER JOHN sold $12.9M2026-07-14 · OYLER JOHN sold $12.5M2026-07-14 · OYLER JOHN sold $11.9M2026-07-17 · OYLER JOHN sold $11.2M2026-07-16 · OYLER JOHN sold $10.2M2026-07-13 · OYLER JOHN sold $8.0M2026-08-10 · OYLER JOHN sold $7.6M2026-08-12 · OYLER JOHN sold $7.5M2026-07-16 · OYLER JOHN sold $6.6M2026-07-21 · OYLER JOHN sold $6.3M2026-07-16 · OYLER JOHN sold $6.2M2026-08-10 · OYLER JOHN sold $5.7M2026-08-12 · OYLER JOHN sold $5.5M2026-09-28 · Wang Xiaodong sold $5.3M2026-08-11 · OYLER JOHN sold $5.3M2025-12-15 · OYLER JOHN sold $5.1M2026-08-12 · OYLER JOHN sold $5.1M2026-07-21 · OYLER JOHN sold $5.0M2026-08-11 · OYLER JOHN sold $4.9M2026-08-11 · OYLER JOHN sold $4.9M2026-07-21 · OYLER JOHN sold $4.9M2026-07-20 · OYLER JOHN sold $4.8M2026-07-16 · OYLER JOHN sold $4.8M2026-07-17 · OYLER JOHN sold $4.7M2026-07-20 · OYLER JOHN sold $4.5M2026-08-10 · OYLER JOHN sold $4.4M2025-12-15 · OYLER JOHN sold $4.4M2026-07-16 · OYLER JOHN sold $4.2M2026-08-11 · OYLER JOHN sold $4.2M2026-07-15 · OYLER JOHN sold $4.0M2026-09-08 · Wang Xiaodong sold $3.7M2026-10-13 · Wang Xiaodong sold $3.6M2025-12-15 · OYLER JOHN sold $3.3M2026-07-16 · OYLER JOHN sold $3.0M2026-08-11 · OYLER JOHN sold $2.9M2026-09-08 · Wang Xiaodong sold $2.6M2026-07-13 · OYLER JOHN sold $2.6M2026-10-13 · Wang Xiaodong sold $2.5M2026-09-30 · CHAN LEE filed to sell $407.3K2026-09-08 · XIAODONG WANG filed to sell $47.1M2026-09-01 · TITUS BENJAMIN BALL filed to sell $47.0K2026-08-25 · CORAZON D. SANDERS filed to sell $788.5K2026-08-25 · XIAOBIN WU filed to sell $5.6M2026-08-11 · CHAN LEE filed to sell $718.7K2026-08-10 · JOHN V OYLER filed to sell $83.9M2026-08-03 · AARON ROSENBERG filed to sell $361.8K2026-07-30 · CHAN LEE filed to sell $337.9K2026-07-22 · CHAN LEE filed to sell $637.7K2026-07-14 · JOHN V OYLER filed to sell $156.1M2026-07-10 · PAN-OYLER FOUNDATION filed to sell $15.0M2026-07-10 · JOHN V OYLER filed to sell $45.4M2026-06-23 · JOHN OYLER filed to sell $933.6K2026-06-23 · XIAOBIN WU filed to sell $356.9K2026-06-23 · LAI WANG filed to sell $295.6K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ONC: institutional holders (13F)

13F holdings, latest reported quarter
BAKER BROS. ADVISORS LP
8,801,567 sh
$2.5B
PRIMECAP MANAGEMENT CO/CA/
5,007,931 sh
$1.4B
Capital International Investors
4,210,221 sh
$1.2B
FMR LLC
2,478,527 sh
$706.3M
Capital World Investors
2,249,582 sh
$641.1M

Congress trades in ONC

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ONC planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
CHAN LEE
Filed 2026-09-30
$407.3K
XIAODONG WANG
Filed 2026-09-08
$47.1M
TITUS BENJAMIN BALL
Filed 2026-09-01
$47.0K
CORAZON D. SANDERS
Filed 2026-08-25
$788.5K
XIAOBIN WU
Filed 2026-08-25
$5.6M

ONC mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ULTRACHINA PROFUND
$873.5K position · as of 2026-07-31
4.3%
Baird Chautauqua International Growth Fund
$51.1M position · as of 2026-06-30
3.9%
PRIMECAP Odyssey Growth Fund
$184.9M position · as of 2026-07-31
3.0%
Baird Chautauqua Global Growth Fund
$13.0M position · as of 2026-06-30
2.9%
VanEck Biotech ETF
$11.1M position · as of 2026-06-30
2.8%
PRIMECAP Odyssey Aggressive Growth Fund
$204.2M position · as of 2026-07-31
2.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
62 registered trials, 52 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
34
Phase 1
25 active
4
Phase 2
4 active
15
Phase 3
14 active
1
Not applicable
1 active
8
Multi-phase
8 active
What changed recently
A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral S
2026-10-24 · Recruiting → Completed
Phase 1
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticanc
2026-10-21 · Completion moved 2027-09-30 → 2028-08-31
Phase 1
A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor
2026-10-10 · Completion moved 2026-09-30 → 2026-10-31
Phase 1
A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395
2026-10-09 · Not Yet Recruiting → Recruiting
Phase 1
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B
2026-10-06 · Completion moved 2026-11 → 2027-03
PHASE1,PHASE2
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese
2026-09-19 · Not Yet Recruiting → Recruiting
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · John V. Oyler
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$18.9M
$11.4M
$7.1M
+9%
+15%
2022
$18.0M
$11.2M
$6.4M
+33%
+11%
2021
$16.7M
$22.9M
$5.1M
+63%
+25%
2020
$14.4M
$40.7M
$5.2M
+56%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $339.5M sold by insiders over 180 days, 167 funds added last quarter, $139.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ONC financials

Revenue growth
+40.2%
XBRL, annual
Net margin
5.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$6.1B
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+10.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$1.3B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.21x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
1.38x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
+14.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+8.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
+43.1%
operating income after a 24.5% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on capital employed
+16.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
878.21x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$554.2B
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
+0.2%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$5.3B$3.8B$2.5B$1.4B
Gross profit$4.7B$3.2B$2.1B$1.1B
Operating income$447.1M-$568.2M-$1.2B-$1.8B
Net income$286.9M-$644.8M-$881.7M-$2.0B
EPS (diluted)0.19-0.47-0.65-1.49
Operating cash flow$1.1B-$140.6M-$1.2B-$1.5B
Cash$4.5B$2.6B$3.2B$3.9B
Long-term debt$961.9M$166.5M$1.4B$1.4B
SEC XBRL, fiscal years, as known on 2026-10-27

ONC Stock Sonar score 6/7 axes

Find similar shapesCompare

ONC ranks highest on profitability (88th percentile) and institutional and government (85th), and lowest on insider conviction (1st), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
88
Inputs
  • Return on equity+14.7% · 87 pct, sector of 545
  • Return on assets+8.5% · 88 pct, sector of 691
  • Return on invested capital+43.1% · 82 pct, sector of 45
  • Return on capital employed+16.6% · 94 pct, sector of 576
Financial health
69
Inputs
  • Debt to equity0.21x · 45 pct, sector of 352
  • Cash flow to debt1.38x · 94 pct, sector of 371
Growth
73
Inputs
  • Revenue growth, YoY+40.2% · 73 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
0
Inputs
  • Net Form 4 buying (codes P and S), 180d-$303.4M · 1 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
85
Inputs
  • Funds adding, latest quarter167 · 85 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
52
Inputs
  • Short interest, % of float+2.4% · 71 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+14.0% · 33 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ONC filings, in plain words

Are BeOne Medicines insiders buying or selling ONC?

In the 180 days to 2026-10-27, BeOne Medicines insiders were net sellers, a net $339.5M across purchases and sales reported on Form 4, by 12 sellers.

Are there planned insider sales of ONC?

Yes. 9 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $139.2M of stock; the latest, by CHAN LEE, was filed 2026-09-30.

Read the full summary

In the 180 days to 2026-10-27, BeOne Medicines insiders were net sellers of ONC, a net $339.5M across purchases and sales reported on Form 4 by 12 sellers. 16% of the 154 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 9 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $139.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies